Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05169424 · ClinicalTrials.gov registry record
A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 9,117
- Enrollment target
NCT05169424 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 9,117 participants.
The verdict
NCT05169424 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 9,117 participants
- Enrollment target
Study Summary
This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD. The purpose of this study is to find out how well the treatments worked. Researchers compare the time to first COPD flare-up (exacerbation) between the 2 treatments. The study analyses anonymous data from pharmacy claims collected over 3.5 years.
Interventions
- DEVICE Trelegy Ellipta
- DEVICE Stiolto Respimat
- DRUG Tiotropium + Olodaterol (5/5 mcg)
- DRUG Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,117 participants |
| Start Date | 2021-12-17 |
| Est. Completion | 2021-12-27 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05169424
The ClinicalTrials.gov registry entry for NCT05169424 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 9,117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trelegy Ellipta is the first listed.
NCT05169424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05169424 about?
NCT05169424 is a clinical study titled "A Study in the US Based on Pharmacy and Medical Claims That Compares How Well Stiolto® and Trelegy® Work in People With Chronic Obstructive Pulmonary Disease (COPD)". This study looks at data from people with chronic obstructive pulmonary disease (COPD). Some used Stiolto Respimat and the others Trelegy Ellipta as their first treatment for COPD. The purpose of this study is to find out how well the treatments worked. Researchers compare the time to first COPD fl...
What is the current status of trial NCT05169424?
This trial is currently completed. The enrollment target is 9,117 participants. The study started on 2021-12-17. Estimated completion is 2021-12-27.
What interventions are being tested in trial NCT05169424?
The interventions under investigation include: Trelegy Ellipta (DEVICE), Stiolto Respimat (DEVICE), Tiotropium + Olodaterol (5/5 mcg) (DRUG), Fluticasone Furoate + Umeclidinium + Vilanterol (100/62.5/25 mcg) (DRUG).
Who is sponsoring clinical trial NCT05169424?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.